AI Insight
This Canadian modeling study evaluated the clinical and economic impact of replacing separate COVID-19 and influenza vaccines with mRNA-1083, an investigational combination mRNA vaccine targeting both pathogens, in adults aged 65 and older. Compared to a stand-alone vaccination strategy, the combination approach was projected to prevent approximately 71,074 COVID-19 symptomatic infections, 5,008 hospitalizations, and 935 deaths, alongside reductions of 3,985 influenza infections, 362 hospitalizations, and 69 deaths over one year. The combination strategy also generated an estimated cost-savings of over 90 million Canadian dollars in vaccine administration fees, with an economically justifiable price of $304 per dose at a willingness-to-pay threshold of $50,000 per QALY gained.
Why it matters
If confirmed by ongoing clinical trials, a combination COVID-19 and influenza vaccine could meaningfully reduce disease burden in older Canadian adults while improving vaccination coverage and offering economic value to the public healthcare system. The simplified immunization schedule may also address logistical barriers that currently limit uptake of both vaccines.
⚠️ Preprint – Noch nicht peer-reviewed
Dieser Artikel wurde noch nicht von unabhängigen Experten begutachtet. Die Ergebnisse sind vorläufig und sollten mit Vorsicht interpretiert werden.
Aims: COVID-19 and influenza continue to impose a substantial burden on the Canadian healthcare system, particularly among adults aged greater than 65 years. This study compared the clinical and economic outcomes of a Stand-alone vaccination strategy with separate influenza and COVID-19 vaccines versus a Combination strategy incorporating mRNA-1083, an investigational vaccine targeting both infections. Methods: The study adopted the public healthcare payer perspective and adapted a previously published static model to predict COVID-19 and influenza infections across a one-year time horizon. Relative vaccine effectiveness (rVE) for mRNA-1083 against COVID-19 compared with the stand-alone vaccine (SPIKEVAX) was based on the pivotal clinical trial of mRNA-1083s COVID-19 component (mRNA-1283). For influenza, no incremental VE was assumed versus the adjuvanted stand-alone vaccine (FLUAD). Infections were modeled independently. Clinical outcomes included symptomatic infections, hospitalizations, and deaths. The economically justifiable price (EJP) was calculated at the willingness-to-pay (WTP) threshold of $50,000 per quality-adjusted life-year (QALY) gained. mRNA-1083 uptake was assumed to yield absolute increases in COVID-19 and influenza coverage by 10% and 3%, respectively. Results: Compared with the Stand-alone strategy, the Combination strategy was projected to reduce the number of COVID-19-related symptomatic infections, hospitalizations, and deaths (n=71,074; 5,008; 935, respectively), and corresponding influenza outcomes (n=3,985; 362; 69, respectively). The use of mRNA-1083 within the Combination strategy generated a cost-savings of $90,440,471 in vaccine administration fees and an EJP of $304 per dose. Results were sensitive to rVE, coverage, administration fees, mortality and incidence. Limitations: mRNA-1083s rVE is being evaluated in clinical trials and the impact of mRNA-1083 on vaccine coverage and administration fees is uncertain. Conclusions: mRNA-1083 may reduce the burden of COVID-19 and influenza in adults aged greater than 65 years in Canada, while offering good economic value because it has the potential to increase coverage and VE while reducing administration fees.